DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tafamidis
Tafamidis
Specialty Pipeline Monthly Update
May 2019 New Drugs
Foldrx Pharmaceuticals, a Pfizer Company a Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
Long-Term Safety and Efficacy of Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy: Results up to 6 Years
211172Orig1s000
Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group Assessment of Manufacturer Submission
VYNDAQEL Are Not Substitutable on a Per Mg Basis
Design and Rationale of the Phase 3 Tafamidis in Transthyretin Cardiomyopathy
Mrx CLINICAL ALERT
Wednesday, June 12, 2019 4:00Pm
2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
Efficacy of Patisiran in Patients with Hattr
Prior Authorization and Step Therapy Criteria
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Clinical Trial Results
Lists of Medicinal Products for Rare Diseases in Europe*
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Top View
Australian Public Assessment Report for Tafamidis and Tafamidis Meglumine
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Lumicera Specialty Drug List
Self-Administered Specialty Drug List
Orphan Drug Designation List
SOM BIOTECH | the Drug Repositioning Company | © 2014 Non-Confidential Success Examples in Repurposing
National Drug List Drug List — Four Tier Drug Plan
Survival in Transthyretin Familial Amyloid Polyneuropathy: a Review
Pharmacy Specialty Drug Policies
Vyndaqel, INN-Tafamidis
Indirect Comparison of Patisiran and Tafamidis for Treatment Of
Drug Benefit Guide
Reimbursement Criteria for Frequently Requested Drugs
Medicare Model Guidelines Draft V8.0 1 of 97
Inotersen (Tegsedi™) EOCCO POLICY
(Tafamidis) Vyndaqel® (Tafamidis Meglumine) (Oral) Document Number: IC-0401 Last Review Date: 10/01/2019 Date of Origin: 07/01/2019 Dates Reviewed: 07/2019, 10/2019
PHARMACY UPDATE June 24, 2019 UPDATE #19-012 Page 1 of 8
Mandatory Specialty Drug List
Long-Term Effects of Tafamidis for the Treatment of Transthyretin Familial Amyloid Polyneuropathy
Pharmacologic Treatment of Transthyretin-Mediated Amyloidosis
Vyndamax™) / Tafamidis Meglumine (Vyndaqel®
New Brunswick Drug Plans Formulary
Drug Information Center Highlights of FDA Activities – 05/01/19 – 05/31/19
Specialty Pipeline MONTHLY UPDATE
Orphan Drugs in Asia Report 2014
Tegsedi Vyndamax and Vyndaqel
MI Medicaid Clinical and PA Criteria
Vyndaqel-Orphan-Maintenance-Assessment-Report-Post-Authorisation En.Pdf
Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value
Inotersen and Patisiran for Hereditary Transthyretin Amyloidosis: Effectiveness and Value
Product Monograph (Download PDF, 403KB)
Tafamidis, a Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade
Tafamidis Tafamidis Meglumine and Placebo
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
CHANGES to the HIGHMARK DRUG FORMULARIES Following Is the Fourth Quarter 2019 Update to the Highmark Drug Formularies and Pharmaceutical Management Procedures
Vyndaqel-Epar-Public-Assessment-Report En.Pdf
Prior Authorization — Premium
State of Louisiana
049 Retail Pharmacy Prior Authorization Policy
Orphan Drug Designations and Approvals List As of 12‐01‐2014
Prescription Formulary
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
PCORI Health Care Horizon Scanning Status Report
(CHMP) Draft Agenda for the Meeting on 28-31 May 2018
Vyndaqel.Pdf
211996Orig1s000 212161Orig1s000
Division of Medical Services Contents
Drugs Limited to Specific Pharmacies | Kaiser Permanente Washington
(Tafamidis) – New Orphan Drug Approvals
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016